The administration of a methylprednisolone infusion following acute spinal cord injury was widely adopted following the report of the results of the second national acute spinal cord injury study in 1990. 1 Subsequent clinical studies and critical reviews of the study methodology and results have challenged the validity of the initial conclusions. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Therefore, a current systematic review was conducted to provide evidence-based ABSTRACT: Background: A systematic review of the evidence pertaining to methylprednisolone infusion following acute spinal cord injury was conducted in order to address the persistent confusion about the utility of this treatment. Methods: A committee of neurosurgical and orthopedic spine specialists, emergency physicians and physiatrists engaged in active clinical practice conducted an electronic database search for articles about acute spinal cord injuries and steroids, from January 1, 1966 to April 2001, that was supplemented by a manual search of reference lists, requests for unpublished additional information, translations of foreign language references and study protocols from the author of a Cochrane systematic review and Pharmacia Inc. The evidence was graded and recommendations were developed by consensus. Results: One hundred and fifty-seven citations that specifically addressed spinal cord injuries and methylprednisolone were retrieved and 64 reviewed. Recommendations were based on one Cochrane systematic review, six Level I clinical studies and seven Level II clinical studies that addressed changes in neurological function and complications following methylprednisolone therapy. Conclusions: There is insufficient evidence to support the use of high-dose methylprednisolone within eight hours following an acute closed spinal cord injury as a treatment standard or as a guideline for treatment. Methylprednisolone, prescribed as a bolus intravenous infusion of 30 mg per kilogram of body weight over fifteen minutes within eight hours of closed spinal cord injury, followed 45 minutes later by an infusion of 5.4 mg per kilogram of bodyweight per hour for 23 hours, is only a treatment option for which there is weak clinical evidence (Level I-to II-1). There is insufficient evidence to support extending methylprednisolone infusion beyond 23 hours if chosen as a treatment option.
C. Data identification
The following electronic database search was conducted by the committee chair: a) PubMed MEDLINE, January 1, 1966 to April 2001 using the terms 'spinal cord injury/drug therapy' [MeSH] and 'steroids/therapeutic use'[MeSH], limited to 'Human'. b) CINAHL, 1982 to 2001 using the terms 'spinal cord injury ' and 'steroids'. c) HealthSTAR, 1990 to 2000 using the terms 'spinal cord injury'and 'steroids'. d) Cochrane Database of Systematic Reviews. e) AHCPR: National Guideline Clearinghouse. f) ACP-ASIM Clinical Practice Guidelines g) CPG Infobase of the Canadian Medical Association.
An additional manual search was conducted using reference lists from selected publications. Additional unpublished information and study protocols were requested from the author of the Cochrane review and Pharmacia Inc.
D. Data selection
Prior to meeting, the committee determined that only information fulfilling the following criteria would be considered:
a) Inclusion criteria
Acute closed spinal cord injuries; methylprednisolone; clinical trials including randomized and nonrandomized studies; overviews; critical commentary of published clinical studies; clinical outcomes and complications; study design and data analysis.
b) Exclusion criteria
Articles confined to the pediatric population; gunshot or open spinal cord injuries; nontraumatic spinal cord injury; animal experiments; nonsteroid therapy; and, articles confined to editorial comment that did not directly address clinical data.
Complete reprints were obtained of all articles including foreign language articles that satisfied the inclusion criteria and were distributed to all committee members.
E. Evaluation of evidence
The validity of clinical studies and overviews were assessed according to guides published by the Evidence-Based Working Group and assigned a level of evidence by consensus by vote, within the hierarchy of evidence recommended by the Canadian Task Force on the Periodic Health Examination (Table 1 ). [12] [13] [14] Only studies assigned Level I or Level II evidence were evaluated and classified by consensus by vote for treatment effect of methylprednisolone infusion following acute closed spinal cord injury. Controlled studies that demonstrated a low false positive treatment effect (p<0.05) were classified as positive despite the lack of confidence levels and absence of data to calculate magnitude of the false-negative (beta) error. Controlled studies with a high false-positive treatment effect (p>0.05) were classified as negative and uncontrolled and retrospective studies as indeterminate.
F. Recommendations
Recommendations were derived by unanimous consensus from all committee members and assigned a degree of certainty by level of evidence according to the following classification: a) Standards: Accepted principles of patient management that reflect a high degree of clinical certainty, supported by Level I high-quality homogeneous overviews that include randomized trials with low false-positive (alpha) and low false-negative (beta) errors and in which all trials demonstrate the same treatment effect. b) Guidelines: Management strategies that reflect a moderate clinical certainty, supported by at least one Level I high-quality heterogeneous overview that includes randomized trials with low false-positive (alpha) and low false-negative (beta) errors and in which the majority of the trials demonstrate a particular treatment effect. c) Options: Remaining strategies for which there is unclear THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES 228 I  Evidence obtained from at least one properly  randomized controlled trial  II-1  Evidence obtained from well-designed controlled  trials without randomization  II-2 Evidence obtained from well-designed cohort or case control analytic studies, preferably from more than one centre or research group II-3
Level of Evidence Criteria
Evidence obtained from comparisons between times or places with or without the interventions III Opinions of respected authorities, based on clinical experience, descriptive studies or reports of expert committees (3) 168 (3) No significant difference in neurological outcome for primary groups receiving (NASCIS II) MPSS or naloxone at <14hr post-injury from placebo control subjects at 6wks, 6mos, 1year 62 (3) 67 (3) Significant improvement in unilateral motor score by 4.8 (p=0.03), pin prick by 4.8 (p=0.02) and light touch by 4.6 (p=0.03) at 6mos for those who received MPSS <8 hours post-injury over placebo control subjects by intent-to-treat analysis 62 (5) 65 (5) Significant improvement in unilateral motor score by 5. clinical certainty, supported by Level II high-quality overviews, randomized trials with high-positive (alpha) and high falsenegative (beta) errors, nonrandomized cohort studies and descriptive studies and expert panel reports. Further clinical studies are required to determine their potential benefit.
G. Implementation
The committee's recommendations were adopted by the Canadian Neurosurgical Society and the Canadian Spine Society at their respective annual general meetings on June 15, 2001 and March 21, 2002 . The recommendations were then also forwarded for information and comment to the parent societies of other stakeholders including the Canadian Orthopedic Association, the Canadian Association of Emergency Physicians, the Trauma Network of Canada, the Canadian Association for Physical Medicine and Rehabilitation, the Rick Hansen Foundation and the Canadian Paraplegia Association. A commentary pertaining to the committee's report will be submitted to the Canadian Medical Association Journal.
H. Review and Update
The committee will review pertinent new clinical evidence as it becomes available and modify its recommendations accordingly.
RESULTS

Evidence reviewed
One hundred and fifty-seven citations that specifically addressed spinal cord injuries and methylprednisolone in human subjects were retrieved. Ninety-three citations were excluded from review because they pertained only to basic science and pathophysiology (15) ; nontraumatic spinal cord pathology (20) ; general editorials and comment in pharmacology and nursing journals (20) ; and, editorial, commentary and reviews that did not focus specifically on methylprednisolone in acute spinal cord injury (37) . The committee confined its review to 64 citations that included one metanalysis and 16 clinical studies in human subjects that focused on methylprednisolone, closed spinal cord injuries, outcome, functional relevance, complications, and critical commentary pertaining to methodology. The report by Pointillart et al 15 is an English translation of the study conducted by Petitjean et al. 16 Only the former was reviewed. Kiwierski's retrospective study of dexamethasone, Gabler's retrospective analysis of 31 patients and Epstein's study that did not address high-dose steroids in spinal cord injury were excluded. [17] [18] [19] Studies of penetrating spinal injuries such as those of P r e n d e rgast, Levy and Heary were also excluded. 2 0 -2 2 Recommendations were based on the one metanalysis and the 13 clinical studies summarized in Tables 2 and 3 .
Level I evidence
One Cochrane review and six clinical studies provide Level I evidence about neurological outcome and complications associated with methylprednisolone therapy, including the three National Acute Spinal Cord Injury Studies (NASCIS I, II, and III), the study by Petitjean et al, the study by Matsumoto et al, and the report by Shepard and Bracken that was based on the NASCIS II study subjects. 1 , 1 6 , 2 3 -3 1 B r a c k e n 's Cochrane metanalysis provides Level I-evidence according to the ratings for high-quality overviews by Cook et al. 1 2 , 2 3 , 2 4 For the assessment of neurological outcome from methylprednisolone therapy, this metanalysis did not consider the entire intention-totreat groups of the three North American Spinal Cord Injury Studies (NASCIS I, II, and III), only the under-eight-hour treated subgroups from secondary analyses. All three NASCIS studies and the French study by Petitjean et al 16 fulfilled the criteria of randomization and blinding. The NASCIS studies were multicentre studies while Petitjean's patients were treated at a single center. The NASCIS I study randomized 330 patients and compared the neurological outcome at six weeks, six months and one year in 165 patients who received a 100mg bolus of methylprednisolone and for ten days thereafter against 165 patients who received a 1000mg bolus of methylprednisolone and for ten days thereafter. 25 31 reported the results of four liver enzymes at 24 hours, three days and ten days after the completion of the drug infusion from the 487 patients that had been randomized into the three treatment groups of the NASCIS II study.
Level II evidence
Seven clinical studies provide Level II evidence. The study by Otani et al, 32 only provides Level II-1 evidence despite its prospective randomized design. One hundred and fifty-eight patients were randomized into a methylprednisolone-treated group (82) and a control group that was not "placebo controlled" but rather received drugs excluding corticosteroids "as a rule" (76). It intended to replicate the NASCIS II study but it also provided for optional administration of steroids up to a total dose of 500mg methylprednisolone over seven days at the investigator's discretion. The study lacked a placebo treatment arm. It also lacked detail about randomization, blinding, and components of the outcome measures, and it only analyzed 117 of the 158 patients for outcome. Because it did not fulfill the criteria of a well-designed, randomized, controlled study, it was assigned Level II-1 evidence. The study by Poynton et al 33 provides Level II-2 evidence with a comparison of changes in motor function in a retrospective review of 71 spinal cord injury patients of whom 38 were treated with the NASCIS II methylprednisolone protocol within eight hours of injury and 33 received no methylprednisolone because they were referred more than eight hours after injury. Similarly, the prospective cohort study by Wing et al 34 provides Level-2 evidence about the incidence of avascular necrosis in the femoral and humeral heads following high-dose methylprednisolone therapy in a group of 59 spinal cord injured patients and a group of 32 spinal cord injuries that did not receive methylprednisolone. Level II-3 evidence is available from Gerhart's retrospective population [35] [36] [37] [38] [39] Changes in neurological scores following high-dose methylprednisolone therapy Table 2 summarizes the studies that report changes in neurological examination following high-dose methylprednisolone administration. None of the four Level I studies demonstrate a treatment effect for high-dose methylpredisolone infusion among their primary intention-to-treat groups. 1, 16, [25] [26] [27] [28] [29] Only the subgroups of patients from the NASCIS II study treated within eight hours of injury combined with the data from the French and Japanese data for motor function improvement at six months and one year post-injury demonstrate a modest improvement of 4.1 motor points on one side of the body (CI 0.6,7.6) for high-dose methylprednisolone therapy. 23, 24 Petitjean et al demonstrated no benefit from methylprednisolone at one year while Otani's Level II-1 study supports a treatment benefit from the NASCIS II methylprednisolone protocol but the lowest confidence level falls below the point of clinical benefit. 23, 24 The remaining Level II studies do not support treatment benefit from high-dose methylprednisolone. 33, 38, 39 The risk of complications from high-dose methylprednisolone therapy Table 3 summarizes the evidence concerning complications from high-dose methylprednisolone. The original NASCIS I study suggested a 3.6 relative risk for early wound infections associated with a high-dose protocol that included a total dose over 10 days that approached the 24-hour total dose employed in NASCIS II and III. 1, [25] [26] [27] [28] [29] There was a statistically significant increase of pneumonia in the 48-hour methylprednisolone group and a nonsignificant increase in sepsis and bradycardia in the NASCIS III study. 28, 29 Petitjean et al 16 noted a high incidence of hyperglycemia in almost half of their methylprednisolone treated patients that were analyzed for complications. The other Level I studies including Matsumoto's 30 small series that specifically looked at early complications, failed to identify any statistically significant increased rate of complications from 24-hour highdose methylprednisolone despite a nonsignificant trend towards sepsis with methylprednisolone. Among the Level II studies, Otani 32 reported early hyperglycemia, glycosuria and abnormal liver function tests in the methylprednisolone group which could be of significance in the older and diabetic patients and G a l a n d i u k 3 8 reported that vital immune responses were adversely affected, pneumonia was more prevalent and hospitalization more prolonged in the methylprednisolone group.
Cost Implications
Cost estimates were obtained from the Pharmacy at the Queen Elizabeth II Health Science Centre in Halifax for the NASCIS II and III protocols for a 75Kg patient. Costs were based on the cost of the respective 1000mg, 500mg and 125mg vials of methylprednisolone required to prepare the bolus infusion of 2250mg and the subsequent hourly infusions of 405mg per hour. The NASCIS II and III protocols would incur a modest cost of $322.02 and $579.32 respectively per patient. These cost estimates did not include nursing time, the cost of the intravenous carrier solution and intravenous administration set or the cost for the use of equipment such as infusion pumps.
DISCUSSION
Level I and II evidence for benefit from methylprednisolone therapy following acute closed spinal cord injury is inconsistent.
Only the under eight hour subgroups in NASCIS II suggested any neurological benefit at six months and one year after injury and this was supported by the methodologically flawed subsequent study by Otani et al. 1, 23, 27, 32 However, while the study by Petitjean et al was underpowered, it demonstrated no benefit at one year from methylprednisolone administered within eight hours of injury. 15, 16 The apparent post hoc derivation of the NASCIS II sub-groups have been criticized despite the author's assertion that the under eight hour window was based on an a priori hypothesis about early versus late therapy and determined by the median time to injury. [3] [4] [5] [6] [7] [8] [9] [10] [11] The analyses of these NASCIS II subgroups generate hypothesis for further study but the conclusions from the analyses to date cannot be regarded as conclusive evidence of benefit from the NASCIS II methylprednisolone protocol. This conclusion is emphasized in two other recent systematic reviews and the clinical guidelines for the management of acute cervical spine and spinal cord injuries developed by the Section on Disorders of the Spine and Peripheral Nerves of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons. 5, 8, 11 The fact that the controversial NASCIS II subgroups comprise 56% of the weighting in Bracken's Cochrane metanalysis, diminishes the impact of the conclusion from this metanalysis. 2 3 , 2 4 Unfortunately, we were unable to obtain the additional data required for a further metanalysis of the data from the available studies and for an estimate of the confidence limits for the means.
The benefit of any intervention must consider not only its availability and treatment effect but also its associated morbidity and cost. The current cost of methylprednisolone therapy as per the NASCIS II and III protocols is modest. However, the evidence summarized in Table 3 reveals a trend to increased septic complications including pneumonia, urinary tract infection and hyperglycemia following high dose methylprednisolone therapy. Although the evidence does not demonstrate a statistically significant risk for serious complications from 24-hour high-dose methylprednisolone therapy, it does suggest a higher risk for septic complications and hyperglycemia with potential adverse consequences for older patients and patients with co-morbidities that could negate any therapeutic benefit. 10 Hyperglycemia may adversely affect the metabolic response to the spinal cord injury. While Sauerland et al 40 concluded that a single bolus of high dose methylprednisolone is not associated with a significant increase in adverse effects in a large population of surgical patients, 14 of 17 relevant gastrointestinal bleeding events occurred in patients with acute spinal cord injuries receiving steroids.
Not only is it essential to determine whether the evidence demonstrates a treatment effect but whether that treatment effect has clinical relevance. Acute spinal cord injury patients normally recover some neurological function. Prior to the adoption of the NASCIS II and III methylprednisolone protocols, late neurological recovery was observed in up to 40% of cervical spinal injuries with ASIAmotor score gains of 8.6 ± 4.7 between one month and one year post-injury. [41] [42] [43] [44] Such neurological recovery is influenced by the severity of injury; the age of the patient; the level of the injury whether cervical, upper thoracic or thoraco-lumbar; and, the presence of any motor preservation at the zone of injury. [43] [44] [45] [46] Incomplete tetraplegic patients typically gain the most motor points, more than incomplete and complete paraplegics. [46] [47] [48] Changes in motor scores and functional grades do not reflect the number or strength of functioning muscles. A gain of a few motor points over several muscles below a complete cord lesion may convert a patient from a Frankel or ASIA grade A to a C functional grade, but it will not result in useful new function unless either antigravity strength is restored; or, a Frankel or ASIAgrade D is achieved. 46, 49, 50 Cervical injuries may be an exception to this principle, because any retained function in the zone of injury immediately post-injury creates a high probability of attaining Grade 3 strength by one year postinjury at one level below an injury.A gain of even a single motor level to antigravity strength has an enormous functional impact for a tetraplegic patient. 4 3 , 4 8 , 5 1 A more robust motor point recovery of up to 11 motor points in incomplete spinal cord injuries as reported in the NASCIS II under eight hour subgroup following high-dose methylprednisolone could potentially provide an important functional gain in most incomplete spinal cord injuries affecting the cervical spinal cord and the conus if such results could be confirmed by further studies. 52 Without detailed descriptions of the level of injury; motor power at and below the zone of injury; and, the actual muscles that subsequently demonstrate recovery, it is impossible to determine whether the changes in mean motor scores, percentage of motor recovery, changes in spinal level or changes in Frankel or ASIA groups pre and post-treatment as reported in the available Level 1 studies were functionally significant. 1, [25] [26] [27] [28] [29] 51, [53] [54] [55] [56] [57] [58] A c c o r d i n g l y, we cannot entirely disregard the apparent benefit from high-dose methylprednisolone in groups of patients purely on the basis of shortcomings in design and analysis. We are currently at a crossroad of equipoise with regards to highdose methylprednisolone therapy for acute spinal cord injuries. If further studies were to confirm the degree of motor recovery recorded in the subgroup analyses of the NASCIS studies, highdose methylprednisolone therapy could potentially benefit cervical and incomplete thoracolumbar injuries if associated complications are acceptably low. The criticisms of the studies to date provide important direction for better prospective studies of high-dose methylprednisolone in specific groups such as acute complete and incomplete cervical spinal cord injuries. The effect of early administration of high-dose methylprednisolone within eight hours of injury on motor function remains an important primary outcome to be tested, along with such important secondary outcomes as functional impact and morbidity. F i n a l l y, with regards to extending methylprednisolone therapy to 48 hours, NASCIS III did not demonstrate clear benefit from extending the methylprednisolone infusion to 48 hours when the infusion was started within eight hours following the acute spinal cord injury. Again a controversial three to eight hour subgroup that seemed to benefit from extending the infusion to 48 hours was identified from within the primary randomized groups; but, unlike the NASCIS II under eight hour subgroup, this observation has not been verified in any other controlled study. Hence the evidence for extending the infusion to 48 hours begs verification with a further prospective controlled study.
CONCLUSIONS
By linking the Level I and II evidence to recommendations it is clear that there is insufficient evidence to support the use of high-dose methylprednisolone within eight hours following an acute closed spinal cord injury as a treatment standard or as a guideline for treatment. Methylprednisolone prescribed as a bolus intravenous infusion of 30 mg per kilogram of body weight over 15 minutes within eight hours of closed spinal cord injury, followed 45 minutes later by an infusion of 5.4 mg per kilogram of bodyweight per hour for 23 hours is only a treatment option for which there is weak clinical evidence (Level I-to II-1). The suggestion that methylprednisolone infusion should be extended beyond 23 hours if chosen as a treatment option has not been verified. Complications attributable to high dose methylprednisolone therapy have not reached statistical significance in well-designed studies but trends to increased sepsis and hyperglycemia cannot be ignored in the absence of Level I evidence of benefit. Further clinical studies are required to determine its potential benefit.
